Advancement of commercial-ready formulation supports scalability and late-stage development SAN DIEGO, June 30, 2026 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
